Toth PP - Search Results

1

Clinical characteristics, patterns of lipid-lowering medication use, and health care resource utilization and costs among patients with atherosclerotic cardiovascular disease.

Power TP, Ke X, Zhao Z, Bonine NG, Cziraky MJ, Grabner M, Barron JJ, Quimbo R, Vangerow B, Toth PP. Power TP, et al. Among authors: toth pp. Vasc Health Risk Manag. 2018 Feb 5;14:23-36. doi: 10.2147/VHRM.S146266. eCollection 2018. Vasc Health Risk Manag. 2018. PMID: 29440909 Free PMC article.

2

Niacin extended-release/simvastatin combination therapy produces larger favorable changes in high-density lipoprotein particles than atorvastatin monotherapy.

Toth PP, Thakker KM, Jiang P, Padley RJ. Toth PP, et al. Vasc Health Risk Manag. 2012;8:39-44. doi: 10.2147/VHRM.S22601. Epub 2012 Jan 25. Vasc Health Risk Manag. 2012. PMID: 22323895 Free PMC article. Clinical Trial.

3

Ezetimibe therapy: mechanism of action and clinical update.

Phan BA, Dayspring TD, Toth PP. Phan BA, et al. Among authors: toth pp. Vasc Health Risk Manag. 2012;8:415-27. doi: 10.2147/VHRM.S33664. Epub 2012 Jul 3. Vasc Health Risk Manag. 2012. PMID: 22910633 Free PMC article. Review.

4

The impact of serum lipids on risk for microangiopathy in patients with type 2 diabetes mellitus.

Toth PP, Simko RJ, Palli SR, Koselleck D, Quimbo RA, Cziraky MJ. Toth PP, et al. Cardiovasc Diabetol. 2012 Sep 14;11:109. doi: 10.1186/1475-2840-11-109. Cardiovasc Diabetol. 2012. PMID: 22978715 Free PMC article.

5

Cardiovascular risk in patients achieving low-density lipoprotein cholesterol and particle targets.

Toth PP, Grabner M, Punekar RS, Quimbo RA, Cziraky MJ, Jacobson TA. Toth PP, et al. Atherosclerosis. 2014 Aug;235(2):585-91. doi: 10.1016/j.atherosclerosis.2014.05.914. Epub 2014 May 22. Atherosclerosis. 2014. PMID: 24956532 Free article.

6

Clinical and economic outcomes in a real-world population of patients with elevated triglyceride levels.

Toth PP, Grabner M, Ramey N, Higuchi K. Toth PP, et al. Atherosclerosis. 2014 Dec;237(2):790-7. doi: 10.1016/j.atherosclerosis.2014.09.029. Epub 2014 Oct 17. Atherosclerosis. 2014. PMID: 25463122 Free article.

7

Overview of saxagliptin efficacy and safety in patients with type 2 diabetes and cardiovascular disease or risk factors for cardiovascular disease.

Toth PP. Toth PP. Vasc Health Risk Manag. 2014 Dec 23;11:9-23. doi: 10.2147/VHRM.S75215. eCollection 2015. Vasc Health Risk Manag. 2014. PMID: 25565858 Free PMC article. Review.

8

Burden of First and Recurrent Cardiovascular Events Among Patients With Hyperlipidemia.

Punekar RS, Fox KM, Richhariya A, Fisher MD, Cziraky M, Gandra SR, Toth PP. Punekar RS, et al. Among authors: toth pp. Clin Cardiol. 2015 Aug;38(8):483-91. doi: 10.1002/clc.22428. Epub 2015 Jun 23. Clin Cardiol. 2015. PMID: 26100722 Free PMC article.

9

Considerations for long-term anticoagulant therapy in patients with venous thromboembolism in the novel oral anticoagulant era.

Toth PP. Toth PP. Vasc Health Risk Manag. 2016 Feb 10;12:23-34. doi: 10.2147/VHRM.S88088. eCollection 2016. Vasc Health Risk Manag. 2016. PMID: 26929637 Free PMC article. Review.

10

Triglyceride-rich lipoproteins as a causal factor for cardiovascular disease.

Toth PP. Toth PP. Vasc Health Risk Manag. 2016 May 6;12:171-83. doi: 10.2147/VHRM.S104369. eCollection 2016. Vasc Health Risk Manag. 2016. PMID: 27226718 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

444 results

Search Page

Filters